Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis

Magaly Aceves Martins; Richard  Quinton; Miriam Brazzelli; Moira Cruickshank; Paul Manson; Jemma Hudson; Nick  Oliver; Rodolfo Andrés Hernández; Lorna Aucott; Frederick C W Wu; Waljit S.  Dhillo; Siladitya Bhattacharya; Katie Gillies; Channa N  Jayasena; NIHR Testosterone Efficacy & Safety (TestES) Consortium

doi:10.1111/andr.13156

Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis

Magaly Aceves Martins, Richard Quinton, Miriam Brazzelli, Moira Cruickshank, Paul Manson, Jemma Hudson, Nick Oliver, Rodolfo Andrés Hernández, Lorna Aucott, Frederick C W Wu, Waljit S. Dhillo, Siladitya Bhattacharya, Katie Gillies^* (Corresponding Author), Channa N Jayasena^* (Corresponding Author), NIHR Testosterone Efficacy & Safety (TestES) Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

3 Downloads (Pure)

Abstract

OBJECTIVE: Men with male hypogonadism (MH) experience sexual dysfunction, which improves with testosterone replacement therapy (TRT). However, randomised controlled trials (RCTs) provide little consensus on functional and behavioural symptoms in hypogonadal men; these are often better captured by qualitative information from individual patient-experience.
METHODS: We systematically searched major electronic databases to identify qualitative data from men with hypogonadism, with or without TRT. Two independent authors performed the selection, extraction and thematic analysis of data. Quality of eligible studies was assessed using the Critical Appraisals Skills Programme (CASP) and Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative research (GRADECERQual) tools.
RESULTS: We analysed data from five studies published in nine reports that assessed a total of 284 participants. Published data were only available within North America, with no ethnic minority or other underserved groups included. In addition to sexual dysfunction, men with MH experienced adverse changes in physical strength, perceptions of masculinity, cognitive function and quality of
life. The experience of MH appeared dependent on the source(s) of educational material.
DISCUSSION: We propose a patient-centred approach to clinician interactions rather than focusing on discreet MH symptoms. Current evidence about the experience of MH is limited to North America and predominantly white ethnicity, which may not be broadly applicable to other geographic regions.
Broadening our understanding of the MH experience may improve the targeting of information to patients. In addition, a multidisciplinary approach may better address symptoms neither attributable to MH nor alleviated by TRT

Original language	English
Pages (from-to)	625-641
Number of pages	17
Journal	Journal of Andrology
Volume	10
Issue number	4
Early online date	8 Feb 2022
DOIs	https://doi.org/10.1111/andr.13156
Publication status	Published - 20 Apr 2022

Bibliographical note

Acknowledgments
We are indebted to members of the patient panel for their feedback and comments.
Funding
This paper presents independent research funded by the National Institute for Health Research (NIHR) and supported by the NIHR Biomedical Research Centre at Imperial College Healthcare NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This project was supported by an NIHR Health Technology Assessment grant (17/68/01). The Section of Endocrinology and Investigative Medicine, Imperial College London is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH- 2009- 241592 EuroCHIP grant and is supported by the NIHR Biomedical Research Centre Funding Scheme. The following authors are also funded as follows: NIHR Research Professorship (WSD); NIHR Post-Doctoral
Fellowship (CNJ).

Keywords

male hypogonadism
testosterone replacement therapy
qualitative systematic review

Access to Document

10.1111/andr.13156

Aceves_etal_A_Identifying_The_Outcomes_AAM
This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited
Accepted author manuscript, 520 KBLicence: Unspecified
Aceves‐Martins_etal_Andro_Identifying_the_Outcomes_VOR
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Final published version, 715 KBLicence: CC BY

Cite this

Aceves Martins, M., Quinton, R., Brazzelli, M., Cruickshank, M., Manson, P., Hudson, J., Oliver, N., Hernández, R. A., Aucott, L., Wu, F. C. W., Dhillo, W. S., Bhattacharya, S., Gillies, K., Jayasena, C. N., & NIHR Testosterone Efficacy & Safety (TestES) Consortium (2022). Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis. Journal of Andrology, 10(4), 625-641. https://doi.org/10.1111/andr.13156

Aceves Martins, M, Quinton, R, Brazzelli, M , Cruickshank, M, Manson, P, Hudson, J, Oliver, N, Hernández, RA , Aucott, L, Wu, FCW, Dhillo, WS, Bhattacharya, S , Gillies, K, Jayasena, CN & NIHR Testosterone Efficacy & Safety (TestES) Consortium 2022, 'Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis', Journal of Andrology, vol. 10, no. 4, pp. 625-641. https://doi.org/10.1111/andr.13156

@article{8ebb2d93c5d34a2fbbddcb15d0e9aad1,

title = "Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis",

abstract = "OBJECTIVE: Men with male hypogonadism (MH) experience sexual dysfunction, which improves with testosterone replacement therapy (TRT). However, randomised controlled trials (RCTs) provide little consensus on functional and behavioural symptoms in hypogonadal men; these are often better captured by qualitative information from individual patient-experience.METHODS: We systematically searched major electronic databases to identify qualitative data from men with hypogonadism, with or without TRT. Two independent authors performed the selection, extraction and thematic analysis of data. Quality of eligible studies was assessed using the Critical Appraisals Skills Programme (CASP) and Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative research (GRADECERQual) tools. RESULTS: We analysed data from five studies published in nine reports that assessed a total of 284 participants. Published data were only available within North America, with no ethnic minority or other underserved groups included. In addition to sexual dysfunction, men with MH experienced adverse changes in physical strength, perceptions of masculinity, cognitive function and quality oflife. The experience of MH appeared dependent on the source(s) of educational material.DISCUSSION: We propose a patient-centred approach to clinician interactions rather than focusing on discreet MH symptoms. Current evidence about the experience of MH is limited to North America and predominantly white ethnicity, which may not be broadly applicable to other geographic regions.Broadening our understanding of the MH experience may improve the targeting of information to patients. In addition, a multidisciplinary approach may better address symptoms neither attributable to MH nor alleviated by TRT",

keywords = "male hypogonadism, testosterone replacement therapy, qualitative systematic review",

author = "{Aceves Martins}, Magaly and Richard Quinton and Miriam Brazzelli and Moira Cruickshank and Paul Manson and Jemma Hudson and Nick Oliver and Hern{\'a}ndez, {Rodolfo Andr{\'e}s} and Lorna Aucott and Wu, {Frederick C W} and Dhillo, {Waljit S.} and Siladitya Bhattacharya and Katie Gillies and Jayasena, {Channa N} and {NIHR Testosterone Efficacy & Safety (TestES) Consortium}",

note = "Acknowledgments We are indebted to members of the patient panel for their feedback and comments. Funding This paper presents independent research funded by the National Institute for Health Research (NIHR) and supported by the NIHR Biomedical Research Centre at Imperial College Healthcare NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This project was supported by an NIHR Health Technology Assessment grant (17/68/01). The Section of Endocrinology and Investigative Medicine, Imperial College London is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH- 2009- 241592 EuroCHIP grant and is supported by the NIHR Biomedical Research Centre Funding Scheme. The following authors are also funded as follows: NIHR Research Professorship (WSD); NIHR Post-Doctoral Fellowship (CNJ). ",

year = "2022",

month = apr,

day = "20",

doi = "10.1111/andr.13156",

language = "English",

volume = "10",

pages = "625--641",

journal = "Journal of Andrology",

issn = "0196-3635",

publisher = "American Society of Andrology Inc.",

number = "4",

}

TY - JOUR

T1 - Identifying the outcomes important to men with hypogonadism

T2 - a qualitative evidence synthesis

AU - Aceves Martins, Magaly

AU - Quinton, Richard

AU - Brazzelli, Miriam

AU - Cruickshank, Moira

AU - Manson, Paul

AU - Hudson, Jemma

AU - Oliver, Nick

AU - Hernández, Rodolfo Andrés

AU - Aucott, Lorna

AU - Wu, Frederick C W

AU - Dhillo, Waljit S.

AU - Bhattacharya, Siladitya

AU - Gillies, Katie

AU - Jayasena, Channa N

AU - NIHR Testosterone Efficacy & Safety (TestES) Consortium

N1 - Acknowledgments We are indebted to members of the patient panel for their feedback and comments. Funding This paper presents independent research funded by the National Institute for Health Research (NIHR) and supported by the NIHR Biomedical Research Centre at Imperial College Healthcare NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This project was supported by an NIHR Health Technology Assessment grant (17/68/01). The Section of Endocrinology and Investigative Medicine, Imperial College London is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH- 2009- 241592 EuroCHIP grant and is supported by the NIHR Biomedical Research Centre Funding Scheme. The following authors are also funded as follows: NIHR Research Professorship (WSD); NIHR Post-Doctoral Fellowship (CNJ).

PY - 2022/4/20

Y1 - 2022/4/20

N2 - OBJECTIVE: Men with male hypogonadism (MH) experience sexual dysfunction, which improves with testosterone replacement therapy (TRT). However, randomised controlled trials (RCTs) provide little consensus on functional and behavioural symptoms in hypogonadal men; these are often better captured by qualitative information from individual patient-experience.METHODS: We systematically searched major electronic databases to identify qualitative data from men with hypogonadism, with or without TRT. Two independent authors performed the selection, extraction and thematic analysis of data. Quality of eligible studies was assessed using the Critical Appraisals Skills Programme (CASP) and Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative research (GRADECERQual) tools. RESULTS: We analysed data from five studies published in nine reports that assessed a total of 284 participants. Published data were only available within North America, with no ethnic minority or other underserved groups included. In addition to sexual dysfunction, men with MH experienced adverse changes in physical strength, perceptions of masculinity, cognitive function and quality oflife. The experience of MH appeared dependent on the source(s) of educational material.DISCUSSION: We propose a patient-centred approach to clinician interactions rather than focusing on discreet MH symptoms. Current evidence about the experience of MH is limited to North America and predominantly white ethnicity, which may not be broadly applicable to other geographic regions.Broadening our understanding of the MH experience may improve the targeting of information to patients. In addition, a multidisciplinary approach may better address symptoms neither attributable to MH nor alleviated by TRT

AB - OBJECTIVE: Men with male hypogonadism (MH) experience sexual dysfunction, which improves with testosterone replacement therapy (TRT). However, randomised controlled trials (RCTs) provide little consensus on functional and behavioural symptoms in hypogonadal men; these are often better captured by qualitative information from individual patient-experience.METHODS: We systematically searched major electronic databases to identify qualitative data from men with hypogonadism, with or without TRT. Two independent authors performed the selection, extraction and thematic analysis of data. Quality of eligible studies was assessed using the Critical Appraisals Skills Programme (CASP) and Grading of Recommendations Assessment, Development and Evaluation-Confidence in the Evidence from Reviews of Qualitative research (GRADECERQual) tools. RESULTS: We analysed data from five studies published in nine reports that assessed a total of 284 participants. Published data were only available within North America, with no ethnic minority or other underserved groups included. In addition to sexual dysfunction, men with MH experienced adverse changes in physical strength, perceptions of masculinity, cognitive function and quality oflife. The experience of MH appeared dependent on the source(s) of educational material.DISCUSSION: We propose a patient-centred approach to clinician interactions rather than focusing on discreet MH symptoms. Current evidence about the experience of MH is limited to North America and predominantly white ethnicity, which may not be broadly applicable to other geographic regions.Broadening our understanding of the MH experience may improve the targeting of information to patients. In addition, a multidisciplinary approach may better address symptoms neither attributable to MH nor alleviated by TRT

KW - male hypogonadism

KW - testosterone replacement therapy

KW - qualitative systematic review

U2 - 10.1111/andr.13156

DO - 10.1111/andr.13156

M3 - Article

SN - 0196-3635

VL - 10

SP - 625

EP - 641

JO - Journal of Andrology

JF - Journal of Andrology

IS - 4

ER -

Identifying the outcomes important to men with hypogonadism: a qualitative evidence synthesis

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this